Smoking and outcomes following personalized antiplatelet therapy in chronic coronary syndrome patients: A substudy from the randomized PATH-PCI trial.
Ying PanTing-Ting WuChang-Jiang DengYi YangXian-Geng HouTuo YanShun WangYing-Ying ZhengXiang XiePublished in: Clinical cardiology (2024)
Regardless of smoking, PAT reduced the MACE and MACCE, with no significant difference in bleeding. This suggests that PAT was an recommendable regimen to CCS patients after PCI, taking into consideration both ischemic and bleeding risk.
Keyphrases
- antiplatelet therapy
- end stage renal disease
- acute coronary syndrome
- percutaneous coronary intervention
- coronary artery disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- acute myocardial infarction
- prognostic factors
- clinical trial
- coronary artery
- randomized controlled trial
- heart failure
- phase iii
- smoking cessation
- phase ii
- oxidative stress
- transcatheter aortic valve replacement
- aortic valve
- blood brain barrier
- subarachnoid hemorrhage